
Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …
A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …
A new phase III study for Eisai’s perampanel (E2007) suggests the first-in-class treatment is effective as an adjunctive treatment of …

